

**genedrive plc**  
**("genedrive" or the "Company")**

**Notice of AGM, Posting of Annual Report and Change of Auditors**

genedrive plc (AIM: GDR), the near patient molecular diagnostics company, announces that copies of its 2019 Annual Report and Accounts and Notice of the 2019 Annual General Meeting ("AGM") have been posted to shareholders and are available on the Group's website <http://www.genedriveplc.com/investor-relations/company-reports.php>

The Company's AGM will be held at 12:00pm on 27 November 2019 at 46 Grafton Street, Manchester M13 9XX.

The Company also announces the intention to propose to shareholders, for approval at the Company's forthcoming AGM, the appointment of RSM UK Audit LLP as its auditor for the year ending 30 June 2020.

This decision follows a competitive tender process which has been overseen by the Audit and Risk Committee. PwC LLP (PwC), the Company's current auditor, undertook and completed the audit for the year ended 30 June 2019. PwC has confirmed to the Company that it is not aware of any circumstances connected with its termination as auditor that it considers should be brought to the attention of the Board, creditors or shareholders of the Company.

For further details please contact:

**genedrive plc**

David Budd: CEO / Matthew Fowler: CFO

[www.genedriveplc.com](http://www.genedriveplc.com)

+44 (0)161 989 0245

**Peel Hunt LLP**

James Steel / Oliver Jackson

+44 (0)20 7418 8900

**Stanford Capital Partners Limited**

Patrick Claridge / John Howes

+44 (0)20 3815 8880

**Walbrook PR Ltd (Media Relations & Investor Relations)**

Paul McManus / Anna Dunphy

+44 (0)20 7933 8780 or

[genedrive@walbrookpr.com](mailto:genedrive@walbrookpr.com)

+44 (0)7980 541 893 / +44 (0)7876 741

001

**Notes to Editors**

**About genedrive plc**

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive® HCV-ID kit has received CE-IVD Certification and has been launched in Africa and Asia Pacific. genedrive has distribution agreements with subsidiaries of Sysmex Corporation for the distribution of the Genedrive® platform in the EMEA and SE Asia (ex-India), and with ARKRAY Healthcare pvt Ltd for the distribution of the Genedrive® HCV-ID Kit and Genedrive® platform in India. The Company has assays on market for the detection of certain biological targets and has tests in development for tuberculosis (mTB) and Antibiotic Induced Hearing Loss (AIHL).

Further details can be found at: [www.genedriveplc.com](http://www.genedriveplc.com) and [www.genedrive.com](http://www.genedrive.com).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

END

NOABABRTMBBMBPL